Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for TM4SF1-positive Digestive System Tumors
NCT05673434Unknown
- Sponsor
- Changhai Hospital
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
01
Overview
Open-label, single-arm trial of TM4SF1-directed chimeric antigen receptor T cells in digestive system tumours, sponsored by Changhai Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 2 years. Status: unknown.
02
Drugs
TM4SF1-directed chimeric antigen receptor T cells
03
Conditions
digestive system tumours
Beyond the preview
Go deeper on NCT05673434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673434.